| __timestamp | Ionis Pharmaceuticals, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 20140000 | 612613000000 |
| Thursday, January 1, 2015 | 37173000 | 650773000000 |
| Friday, January 1, 2016 | 48616000 | 619061000000 |
| Sunday, January 1, 2017 | 108488000 | 628106000000 |
| Monday, January 1, 2018 | 244622000 | 717599000000 |
| Tuesday, January 1, 2019 | 287000000 | 964737000000 |
| Wednesday, January 1, 2020 | 354000000 | 875663000000 |
| Friday, January 1, 2021 | 186000000 | 886361000000 |
| Saturday, January 1, 2022 | 151000000 | 997309000000 |
| Sunday, January 1, 2023 | 232600000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and Ionis Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Takeda's SG&A expenses have shown a steady increase, peaking at approximately ¥1.05 trillion in 2023, reflecting a 72% rise from 2014. In contrast, Ionis Pharmaceuticals experienced a more volatile trajectory, with expenses surging by over 1,000% from 2014 to 2019, before stabilizing around $232 million in 2023. This stark contrast highlights Takeda's expansive global operations compared to Ionis's focused R&D investments. Notably, 2024 data for Ionis is missing, indicating potential reporting delays or strategic shifts. Such insights are invaluable for investors and industry analysts seeking to navigate the competitive landscape of pharmaceuticals.
Breaking Down SG&A Expenses: Sanofi vs Ionis Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited vs Intra-Cellular Therapies, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Insmed Incorporated
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Pharming Group N.V.
Takeda Pharmaceutical Company Limited and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Perrigo Company plc
Selling, General, and Administrative Costs: Summit Therapeutics Inc. vs Ionis Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Ionis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Ionis Pharmaceuticals, Inc. and CymaBay Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Ionis Pharmaceuticals, Inc. and Veracyte, Inc.
Ionis Pharmaceuticals, Inc. vs Evotec SE: SG&A Expense Trends